MAY 28, 2015 3:47 PM PDT

Herpes-based therapy shows promise for melanoma treatment

WRITTEN BY: Robert Woodard
Melanoma cells: Image shows podosomes (yellow), cell nuclei (blue), actin (red), and an actin regulator (green).A phase III clinical trial has demonstrated the therapeutic benefit of the oncolytic virus Talimogene Laherparepvec (T-VEC) against melanoma, paving the way for a potential novel therapy for patients with metastatic melanoma. T-VEC is the first oncolytic immunotherapy to demonstrate therapeutic benefit against melanoma in a phase III clinical trial.

T-VEC preferentially kills cancer cells. It is based on a cancer-killing herpes virus that has been genetically modified to prevent it from producing the protein that allows it to infect healthy cells. Instead, the virus thrives on a similar version of that protein produced by cancer cells. Inside the cancer cells, the virus selectively multiplies, causing the cancer cells burst open. The virus then spills out into the surrounding area and triggers an enhanced anti-tumor immune response.

Once the immune response has been triggered by T-VEC, it apparently starts to detect and attack cancer throughout the body. The reasons for this are not completely clear, the results of the trial confirmed the effect-even tumors that had not been directly infected by the virus got smaller or disappeared.

In the randomized open-label phase III trial, T-VEC was compared with granulocyte macrophage colony-stimulating factor (GM-CSF) in patients with unresected stage IIIB to IV melanoma. Among the 423 individuals who participated in the trial, 25% responded to the treatment and 16% were still in remission after six months. About 10% of the patients treated had "complete remission," with no detectable cancer remaining.

T-VEC therapy is given by injection. Patients in the trial received a dose every two weeks for up to 18 months. The most common adverse events (AEs) with T-VEC were fatigue, chills, and pyrexia (fever). The only grade 3 or 4 AE occurring in ? 2% of T-VEC-treated patients was cellulitis (2.1%). No fatal treatment-related AEs occurred.

The results indicate that T-VEC has the potential to treat cancer even when the disease has spread to organs throughout the body.

According to Kevin Harrington, professor of biological cancer therapies at the Institute of Cancer Research London who led the work: "This is the big promise of this treatment. It's the first time a virotherapy has been shown to be successful in a phase III trial."

According to scientists, if approved T-VEC could possibly be more widely available for cancer patients by next year.

The study was published in the May 26, 2015 issue of the Journal of Clinical Oncology.

According to the American Cancer Society, in 2015 about 73,870 new melanomas will be diagnosed (about 42,670 in men and 31,200 in women) in the US. The survival rate of stage IIIB and IIIC is around 40% to 59%. The survival rate for stage IV is around 15% to 20%.

(Sources: theguardian.com, Journal of Clinical Oncology, American Cancer Society)
About the Author
You May Also Like
JUL 22, 2021
Immunology
"Stunning" Anti-Inflammatory Effects of a Fermented Food Diet
JUL 22, 2021
"Stunning" Anti-Inflammatory Effects of a Fermented Food Diet
Researchers at Stanford University have found that consuming fermented foods such as yogurt, sauerkraut, and kombucha te ...
AUG 23, 2021
Microbiology
During a Chronic Viral Infection, Immune Cells May Suffer 'Exhaustion'
AUG 23, 2021
During a Chronic Viral Infection, Immune Cells May Suffer 'Exhaustion'
Several viruses are known to cause chronic infections, one is hepatitis C virus (HCV). Researchers studying these infect ...
SEP 07, 2021
Health & Medicine
Think you can pay back your sleep debt this weekend? Think again.
SEP 07, 2021
Think you can pay back your sleep debt this weekend? Think again.
Researchers find that even one night of sleep loss results in impaired functioning and well being.
SEP 28, 2021
Immunology
Cell Therapy Scrubs Tumors, Spares Transplanted Organs
SEP 28, 2021
Cell Therapy Scrubs Tumors, Spares Transplanted Organs
Hepatitis B infections have created a ‘silent epidemic’—infected people don’t display any sympto ...
OCT 14, 2021
Immunology
'Bio-Betters' Form the Next Wave of Cancer Therapies
OCT 14, 2021
'Bio-Betters' Form the Next Wave of Cancer Therapies
  Antibodies are blood proteins with highly specialized functions: to recognize and eliminate bacteria, viruses, an ...
OCT 12, 2021
Health & Medicine
Atopic Dermatitis: A Harbinger of Autoimmune Diseases?
OCT 12, 2021
Atopic Dermatitis: A Harbinger of Autoimmune Diseases?
New research published in Allergy, Asthma & Clinical Immunology found an increased risk of autoimmune disease develo ...
Loading Comments...